
Chronisch-entzündliche Erkrankungen (CEDs)
Sie befinden sich hier:
Klinische Studien (CED)
Anprechpartner
Aktuelle klinische Studien CED
GO-OBSERVE
Europäische prospektive Beobachtungsstudie zum subjektiv (vom Patienten) beurteilten kontinuierlichen klinischen Ansprechen auf SIMPONI bei Erwachsenen mit moderater bis schwerer aktiver Colitis ulcerosa
Anprechpartner: Dr. A. Schirbel, Dr. U.-F. Pape
GA28950 - ETROLIZUMAB
Phase III, double blind, placebo-controlled, multicenter study of the efficacy and safety of Etrolizumab during induction and maintenance in patients with moderate to severe active Ulcerative Colitis who are refractory to or intolerant of TNF inhibitors
Anprechpartner: Dr. A. Schirbel, Dr. U.-F. Pape, Dr. A. Fischer
GA29102 - ETROLIZUMAB VERSUS PLACEBO
Phase III, randomized, double blind, placebo-controlled, multicenter study to evaluate the efficacy (maintenance of remission) and safety of Etrolizumab compared with placebo in patients with moderate to severe active Ulcerative Colitis who are naive to TNF inhibitors
Anprechpartner: Dr. A. Schirbel, Dr. U.-F. Pape, Dr. A. Fischer
Abbvie M14-033 - Adalimumab Hochdosis-Studie bei M. Crohn
A Multicenter, Randomized, Double-Blind Study to Evaluate Higher Versus Standard Adalimumab Dosing Regimens for Induction and Maintenance Therapy in Subjects With Moderately to Severely Active Crohn's Disease and Evidence of Mucosal Ulceration
Anprechpartner: Dr. A. Fischer
EARNEST - Vedolizumab bei chronischer Pouchitis
A Randomized, Double-Blind, Placebo-Controlled Phase 4 Study to Evaluate the Efficacy and Safety of Entyvio (Vedolizumab IV) in the Treatment of Chronic Pouchitis
Anprechpartner: Dr. A. Fischer
GA29144 - Etrolizumab bei M. Crohn
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Etrolizumab as an Induction And Maintenance Treatment For Patients With Moderately to Severely Active Crohn's Disease
Anprechpartner: Dr. A. Fischer
GS-US-419-3895 - Filgotinib bei M. Crohn
Combined Phase 3, Double-blind, Randomized, Placebo-Controlled Studies Evaluating the Efficacy and Safety of Filgotinib in the Induction and Maintenance of Remission in Subjects With Moderately to Severely Active Crohn's Disease
Anprechpartner: Dr. A. Fischer
SELECTION1 - Filgotinib bei Colitis ulcerosa
Combined Phase 2b/3, Double-Blind, Randomized, Placebo-Controlled Studies Evaluating the Efficacy and Safety of Filgotinib in the Induction and Maintenance of Remission in Subjects With Moderately to Severely Active Ulcerative Colitis
Anprechpartner: Dr. A. Fischer
MLN0002SC-3030 - Vedolizumab Subkutanstudie
A Phase 3b Open-label Study to Determine the Long-term Safety and Efficacy of Vedolizumab Subcutaneous in Subjects With Ulcerative Colitis and Crohn's Disease
Anprechpartner: Dr. A. Fischer
MLN0002SC-3031 - Vedolizumab Subkutanstudie
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Vedolizumab Subcutaneous as Maintenance Therapy in Subjects With Moderately to Severely Active Crohn's Disease Who Achieved Clinical Response Following Open-Label Vedolizumab Intravenous Therapy
Anprechpartner: Dr. A. Fischer
RPC01-3101 - Ozanimod bei Colitis ulcerosa
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Oral RPC1063 as Induction and Maintenance Therapy for Moderate to Severe Ulcerative Colitis
Anprechpartner: Dr. A. Fischer
STARDUST - Ustekinumab-Dosisstudie bei M. Crohn
Study of Treat to Target Versus Routine Care Maintenance Strategies in Crohn's Disease Patients Treated With Ustekinumab
Anprechpartner: Dr. A. Fischer
TRIDENT - JNJ-64304500 bei M. Crohn
A phase 2b, randomized, double-blind, placebo-controlled, parallel-group, multicenter protocol to evaluate the safety and efficacy of JNJ-64304500 in subjects with moderately to severely active Crohn's disease
Anprechpartner: Dr. A. Fischer